CStone Pharmaceuticals, a biopharma company focused on developing and commercialising innovative immuno-oncology and molecularly targeted drugs, announced today that it has named Archie Tse, MD, PhD as its new senior vice president, chief translational medicine officer.
Dr Tse is to report to Frank Jiang, MD, PhD, chairman and chief executive officer.
Dr Tse has more than 20 years of global oncology research and clinical development experience and the company says that he will provide a strong addition to its senior leadership team. In this role, Dr Tse will be responsible for the development of assets at the early clinical development stage up to proof of concept. He will manage the development and implementation of clinical biomarkers to support progression of CStone's pipelines. His in-depth understanding of the global oncology space is intended to help further strengthen CStone's core competence and solidify its position among innovative biopharma companies in China.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886